How BeiGene Navigated CDE Clinical Trial Approvals for Tislelizumab in China

Biotech Case Study — CG360-BIOTECH-CASE-030

Published by China Gateway 360 • July 2026

BeiGene’s journey from a Beijing-based startup to a global oncology powerhouse is one of the most instructive case studies in modern biopharmaceutical regulatory strategy. Central to this story is tislelizumab (BGB-A317), an anti-PD-1 monoclonal antibody that became the first Chinese-developed PD-1 inhibitor to receive approval from both the China National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA). This case study examines how BeiGene navigated the Center for Drug Evaluation (CDE) clinical trial approval process in China, the regulatory strategies that accelerated development, and the lessons for both domestic and foreign biotech firms seeking to bring innovative therapies to the Chinese market.

1. Background: BeiGene’s Unique Position as a China-Born Biotech

Founded in 2010 by Chinese-American entrepreneur John Oyler and renowned structural biologist Wang Xiaodong, BeiGene was conceived as a fully global biotech with deep roots in China. Unlike many Chinese biotech companies that focused primarily on biosimilars or me-too drugs, BeiGene set out from the beginning to discover and develop innovative oncology therapies with global potential. The company established dual headquarters in Beijing and Cambridge, Massachusetts, and built research capabilities spanning both countries.

By the time tislelizumab entered preclinical development in 2012, BeiGene had already secured significant venture capital funding and assembled a team with deep experience in both Western regulatory standards and Chinese drug development expectations. This dual fluency would prove critical in navigating the CDE’s evolving requirements for innovative drug approvals.

2. The Drug: Tislelizumab (BGB-A317) — Designed for Differentiation

Tislelizumab is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1). It was engineered with a specific Fc region modification (Fc-silencing via the L235A, L235E, and P329G mutations — the so-called “LALAPG” triple mutant) designed to minimize binding to Fc-gamma receptors and reduce antibody-dependent phagocytosis, a potential mechanism of T-cell depletion and resistance. This differentiated tislelizumab from first-generation PD-1 inhibitors such as Keytruda (pembrolizumab) and Opdivo (nivolumab), which retain Fc-mediated effector function.

BeiGene posited that this Fc-silencing could lead to a more favorable safety profile and potentially enhanced efficacy by preserving the T-cell compartment within the tumor microenvironment. While the clinical significance of this design feature remains debated, it provided a clear regulatory narrative for the CDE: this was not a simple me-too biosimilar but a purposefully engineered next-generation molecule with a distinct mechanism-related rationale.

3. China’s Regulatory Landscape at the Time of Submission

When BeiGene began preparing its first IND for tislelizumab in 2013–2014, China’s drug regulatory environment was in the midst of a major transformation. The CDE was severely understaffed and faced enormous backlogs. The average clinical trial application review time stretched to 12–18 months, and many international companies viewed the Chinese regulatory pathway as unpredictable and opaque.

However, several critical reforms were underway or on the horizon:

• 2015 — the “44 Document” (Guobanfa [2015] No. 44): The State Council issued landmark reforms to accelerate drug and medical device approval, including the introduction of priority review for innovative drugs, expanded CDE staffing, and acceptance of overseas clinical trial data under certain conditions.
• 2017 — ICH Membership: China joined the International Council for Harmonisation (ICH), committing to align domestic regulatory standards with global guidelines, including those for clinical trial design and data integrity.
• 2018 — NMPA Restructuring: The China Food and Drug Administration (CFDA) was restructured into the NMPA, with the CDE receiving expanded authority and resources.
• 2020 — Drug Administration Law Revisions: New provisions explicitly encouraged innovative drug development, established patent linkage and regulatory data protection, and streamlined clinical trial application procedures.

4. CDE Submission Strategy: A Multi-Indication Approach

BeiGene’s CDE submission strategy for tislelizumab was notable for its ambition and methodological sophistication. Rather than pursuing a single indication sequentially, the company adopted a multi-pronged approach that targeted multiple tumor types simultaneously through a series of parallel clinical trials.

4.1 Pre-IND Consultation

In 2014, before submitting the formal IND application, BeiGene engaged the CDE in a pre-IND consultation meeting. This step, though not mandatory at the time, was crucial. BeiGene presented:

• Preclinical pharmacology and toxicology data from both in-house studies and contract research organizations
• The rationale for Fc engineering and the proposed mechanism-of-action advantages
• A proposed clinical development plan covering multiple indications including classical Hodgkin lymphoma (cHL), urothelial carcinoma (UC), non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), and esophageal squamous cell carcinoma (ESCC)
• The proposed bridging strategy between global Phase I data and China-specific trials

The CDE’s feedback during this consultation shaped several aspects of the development plan, including the specific patient populations for initial trials and the required sample sizes for bridging studies.

4.2 IND Submission and Acceptance

BeiGene submitted its first IND for tislelizumab to the CDE in late 2014. The application included extensive preclinical data and a detailed clinical trial protocol for a first-in-human Phase I study that would be conducted in parallel in Australia, the United States, and China. This meant the CDE needed to review not only the China-specific component but also how the global data would be utilized for China registration.

Thanks to the pre-IND engagement and the completeness of the dossier, the CDE accepted the IND and approved the Phase I trial in approximately 10 months — significantly faster than the average review time for 2014–2015.

4.3 The Bridging Study Strategy

A central regulatory question for any global drug seeking China registration is whether local clinical data is required. For tislelizumab, BeiGene employed a hybrid bridging strategy:

• Global Phase I (BGB-A317-001): Conducted in Australia, New Zealand, the United States, and China, enrolling approximately 450 patients across multiple dose-escalation and expansion cohorts. The China cohort enrolled ~100 patients at clinical trial centers in Beijing, Shanghai, and Guangzhou.
• China-Specific Phase II Trials: For the initial approval indication (relapsed/refractory classical Hodgkin lymphoma, r/r cHL), BeiGene conducted a dedicated China-only single-arm Phase II trial (BGB-A317-203) enrolling 70 patients across 10 Chinese sites. This was the pivotal trial for the first NDA submission.
• Global Phase III with China Enrollment: For subsequent indications (UC, NSCLC, HCC, ESCC), BeiGene designed global randomized Phase III trials that included China as a major enrollment region, typically with 30–50% of patients enrolled from Chinese sites.

5. Timeline of Key Regulatory Milestones

6. Key Regulatory Strategies That Accelerated Approval

6.1 Leveraging the Priority Review and Breakthrough Therapy Designation Pathways

Following the 2015–2017 regulatory reforms, the CDE established mechanisms for expedited review of innovative drugs. BeiGene successfully obtained Breakthrough Therapy Designation (BTD) for tislelizumab in 2018 for the r/r cHL indication. BTD provided:

• Intensive CDE guidance throughout development
• Eligibility for rolling review of the NDA submission
• Priority review status, targeting a 6-month review timeline vs. the standard 12 months

6.2 Use of Single-Arm Phase II Data for Initial Approval

The CDE accepted a single-arm, open-label Phase II trial as the pivotal basis for conditional approval in r/r cHL. This was a significant regulatory precedent. The rationale was:

• r/r cHL after failure of autologous stem cell transplant had no approved standard therapy in China
• The objective response rate (ORR) in the trial was 87.1% (61/70 patients), with a complete response rate of 62.9%
• Duration of response was sufficiently mature to demonstrate clinical benefit
• Conditional approval was granted with a post-marketing requirement to conduct a randomized confirmatory trial

6.3 Alignment Between CDE and Global Regulatory Expectations

BeiGene designed its pivotal China trials to meet both CDE and FDA/EMA requirements wherever possible. This “regulatory alignment” strategy meant that:

• China sites used the same protocols, endpoints, and data standards as global sites
• Centralized independent review committees (IRC) evaluated responses for both China and global trials
• Data management and statistical analysis plans followed ICH E6 (GCP) and E9 guidelines
• This consistency allowed the same clinical data package to support submissions to multiple regulators, reducing duplicative work

7. Challenges Encountered

The path was not without obstacles. BeiGene faced several significant challenges:

• CDE Capacity Constraints (2015–2017): Even with priority status, review timelines were affected by the CDE’s limited staffing. BeiGene invested in regulatory affairs staff dedicated to managing CDE communications and responding to information requests within days rather than weeks.
• Site Activation Delays: Clinical trial site activation in China was slower than anticipated, particularly for oncology trials requiring specialized infrastructure. BeiGene pre-selected sites and conducted feasibility assessments before finalizing protocols.
• Evolving CMC Requirements: The Chemistry, Manufacturing, and Controls (CMC) expectations for biologics were in flux as China aligned with ICH guidelines. BeiGene had to generate additional stability data and process characterization information mid-development to satisfy CDE requests.
• Competitive Pressure: Domestic competitors including Junshi Biosciences (toripalimab), Innovent (sintilimab), and Hengrui Medicine (camrelizumab) were all developing PD-1 inhibitors simultaneously, creating a race to market. BeiGene’s strategy of initially targeting a niche indication (cHL) rather than the larger NSCLC market proved wise, as it faced less immediate competition.
• Conditional Approval Post-Market Requirements: The confirmatory trial obligation imposed by the CDE was substantial. BeiGene committed to a randomized Phase III trial comparing tislelizumab to salvage chemotherapy in r/r cHL, which required significant additional investment and patient enrollment.

8. Results and Impact

BeiGene’s CDE strategy for tislelizumab yielded impressive results:

• 5 approved indications in China within 3 years of first approval (cHL, UC, NSCLC squamous, NSCLC non-squamous, HCC, ESCC)
• First Chinese-developed PD-1 to receive FDA approval (ESCC, 2023)
• Conditional to full approval conversion accomplished through successful completion of confirmatory trials
• Market leadership: Tislelizumab became one of the top-selling PD-1 inhibitors in China with significant market share
• Global expansion: Approved in the US, EU, Japan, South Korea, and multiple other markets

As of 2026, tislelizumab is approved in more than 40 countries and has been used to treat over 500,000 patients worldwide. Total revenues for tislelizumab exceeded $1.5 billion in 2025, making it one of the most commercially successful Chinese-origin biologics globally.

9. Lessons for Foreign and Domestic Biotech Firms

10. Conclusion

BeiGene’s navigation of the CDE clinical trial approval process for tislelizumab stands as a landmark case study in modern biopharmaceutical regulatory strategy. The company succeeded by combining deep scientific understanding of its molecule with a sophisticated regulatory approach that anticipated China’s evolving drug approval environment, engaged proactively with CDE reviewers, and designed clinical development programs that could satisfy multiple regulators simultaneously.

The case demonstrates that the regulatory pathway for innovative drugs in China is no longer an obstacle to be overcome but a structured process that can be navigated successfully with the right strategy. For both foreign companies seeking to bring innovative therapies to Chinese patients and domestic biotechs aspiring to global markets, BeiGene’s approach offers a proven template: invest in regulatory capability, engage early and often with the CDE, design for global alignment from the start, and demonstrate the distinctiveness of your therapeutic innovation.

As China’s role in global drug development continues to grow, the lessons from tislelizumab’s journey will only become more relevant. The CDE has evolved into a sophisticated regulatory agency operating on ICH-aligned standards, and companies that treat it as a true partner in drug development — rather than a hurdle to be cleared — will find the path to approval increasingly accessible and predictable.